Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACACB | O00763 | 4/20 | 0.65 |
| ▸ | ACACA | Q13085 | 4/20 | 0.65 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.61 |
| ▸ | MEN1 | O00255 | 1/20 | 0.59 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.59 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.58 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.58 |
| ▸ | LMNA | P02545 | 2/20 | 0.58 |
| ▸ | HPGD | P15428 | 1/20 | 0.58 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.57 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.56 |
| ▸ | POLB | P06746 | 1/20 | 0.56 |
| ▸ | CTDSP1 | Q9GZU7 | 1/20 | 0.56 |
| ▸ | RECQL | P46063 | 1/20 | 0.56 |
| ▸ | MAPT | P10636 | 1/20 | 0.56 |
| ▸ | NPC1 | O15118 | 1/20 | 0.56 |
| ▸ | MMP9 | P14780 | 1/20 | 0.54 |
| ▸ | MMP8 | P22894 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1754100 | 1.00 | ACACB (0.65) | ACACBACACAHSD17B10MEN1KMT2A | |
| SCHEMBL540666 | 1.00 | ACACB (0.65) | ACACBACACAHSD17B10MEN1KMT2A | |
| SCHEMBL5043127 | 0.98 | ACACB (0.63) | ACACBACACAHSD17B10MEN1KMT2A | |
| SCHEMBL3861309 | 0.91 | ACACB (0.56) | ACACBACACAHSD17B10MEN1KMT2A | |
| SCHEMBL7736414 | 0.88 | ACACB (0.77) | ACACBACACAMEN1KMT2AALDH1A1 | |
| SCHEMBL25336459 | 0.84 | MMP9 (0.66) | HSD17B10MEN1KMT2AALDH1A1KDM4E | |
| SCHEMBL247742 | 0.84 | HSD17B10 (0.63) | HSD17B10MEN1KMT2AALDH1A1KDM4E | |
| SCHEMBL8715641 | 0.84 | HSD17B10 (0.75) | HSD17B10MEN1KMT2AALDH1A1KDM4E | |
| SCHEMBL249524 | 0.84 | HSD17B10 (0.63) | HSD17B10MEN1KMT2AALDH1A1KDM4E | |
| SCHEMBL2672977 | 0.84 | HSD17B10 (0.63) | HSD17B10MEN1KMT2AALDH1A1KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 181 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| JP-9241222-A | — | — | None | — | — | JP | disclosed |
| WO-2025119351-A1 | GPR139 AGONIST | 深圳湾实验室 | 2025-06-12 | — | — | WO | disclosed |
| US-20250185669-A1 | ANTI-VIRAL PAINTS AND COATINGS AND ARTICLES COMPRISING SAME | Reactive Surfaces Ltd., LLP (US) | 2025-06-12 | — | — | US | disclosed |
| US-12232498-B2 | Anti-viral paints and coatings and articles comprising same | Reactive Surfaces Ltd., LLP (US) | 2025-02-25 | — | — | US | disclosed |
| US-12110302-B2 | Metal complex, intermediate, and preparation method and application thereof | SHANGHAI INSTITUTE OF ORGANIC CHEMISTRY, CHINESE ACADEMY OF SCIENCES (CN) | 2024-10-08 | — | — | US | disclosed |
| EP-3865494-B1 | METAL COMPLEX, INTERMEDIATE, AND PREPARATION METHOD AND APPLICATION THEREOF | SHANGHAI INST ORGANIC CHEMISTRY CAS (CN) | 2024-07-24 | — | — | EP | disclosed |
| US-20240172762-A1 | ANTI-VIRAL PAINTS AND COATINGS AND ARTICLES COMPRISING SAME | Reactive Surfaces Ltd., LLP (US) | 2024-05-30 | — | — | US | disclosed |
| US-11980192-B2 | Anti-viral paints and coatings and articles comprising same | Reactive Surfaces Ltd., LLP (US) | 2024-05-14 | — | — | US | disclosed |
| US-20240016160-A1 | ANTI-VIRAL PAINTS AND COATINGS AND ARTICLES COMPRISING SAME | Reactive Surfaces Ltd., LLP (US) | 2024-01-18 | — | — | US | disclosed |
| US-11832617-B2 | Anti-viral paints and coatings and articles comprising same | Reactive Surfaces Ltd., LLP (US) | 2023-12-05 | — | — | US | disclosed |
| US-20030018034-A1 | Piperazine compounds and medicinal use thereof | MITSUBISHI PHARMA CORPORATION | 2003-01-23 | — | — | US | disclosed |
| US-6455528-B1 | TUMOR NECROSIS FACTOR ANTAGONIST AND/OR INTERLEUKIN PROMOTER; ANTIALLERGENS, ANTIINFLAMMATORY AGENTS; AUTOIMMUNE DISEASE TREATMENT | MITSUBISHI PHARMA CORPORATION (JP) | 2002-09-24 | — | — | US | disclosed |
| US-6235516-B1 | FROM RHODOCOCCUS GLOBERULUS, RHODOCOCCUS EQUI OR ARTHROBACTER AURESCENS | NOVARTIS AG (CH) | 2001-05-22 | — | — | US | disclosed |
| EP-1029851-A1 | PIPERAZINE COMPOUNDS AND MEDICINAL USE THEREOF | YOSHITOMI PHARMACEUTICAL INDUSTRIES, LTD. (JP) | 2000-08-23 | — | — | EP | disclosed |
| EP-0954571-A1 | BIOCATALYSTS WITH AMINE ACYLASE ACTIVITY | Novartis AG (CH) | 1999-11-10 | — | — | EP | disclosed |
| US-5952527-A | A COMPLEX OF TRANSITIONAL METAL COMPOUND, CYCLOOCTADIENE OR CYCLOPENTADIENE AND 2,2-BIS/DIPHENYLPHOSPHINOAMINO/-5,5',6,6'7,7',8,8'-OCTAHYDRO-1 ,1'-BINAPHTHYL COMPOUND; USED AS HYDROGENATION CATALYST | THE HONG KONG POLYTECHNIC UNIVERSITY (HK) | 1999-09-14 | — | — | US | disclosed |
| US-5919981-A | USING HYDROGENATION 1,1*-BINAPHTHYL-2,2*-DIAMINE AS CHEMICAL INTERMEDIATE | THE HONG KONG POLYTECHNIC UNIVERSITY (HK) | 1999-07-06 | — | — | US | disclosed |
| WO-1997041214-A1 | BIOCATALYSTS WITH AMINE ACYLASE ACTIVITY | NOVARTIS AG (CH) | 1997-11-06 | — | — | WO | disclosed |
| JP-H09241222-A | PRODUCTION OF AMINE | SAGAMI CHEM RES CENTER | 1997-09-16 | — | — | JP | disclosed |
| EP-0399589-A1 | Preparation of N-acyl alkylamines | SHELL INTERNATIONALE RESEARCHMAATSCHAPPIJ B.V. (NL) | 1990-11-28 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12110302-B2 | Metal complex, intermediate, and preparation method and application thereof | AP2M1, AP3M1, AP1M1 | ACACB 1337/4885ACACA 775/4885HSD17B10 1478/4885 |
| US-20030018034-A1 | Piperazine compounds and medicinal use thereof | TNF, IL5, CCR10 | ACACB 1289/4885ACACA 1336/4885HSD17B10 465/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.